- Diurnal has signed a marketing and distribution agreement with Medison Pharma, Israel's leading commercial group for niche healthcare products.

The agreement covers the commercialisation in Israel of Diurnal's novel therapies for adrenal insufficiency, Infacort and Chronocort.

Infacort is expected to be submitted for marketing authorisation in Israel once approved by the European Medicines Agency.

Diurnal anticipates EMA marketing authorisation approval for Infacort could come towards the end of 2017 with the potential of approval in Israel during 2018, based on the European regulatory submission package and clinical trial data.

Story provided by